Isconova and Genocea Biosciences have widened their existing agreement, under which Isconova has given license for using its Matrix M to Genocea Biosciences in vaccines targeting two additional diseases. Currently, Genocea has the right to use Matrix M in vaccines targeting six infectious diseases including programs in its pipeline for herpes simplex virus type-2, Chlamydia trachomatis, and Streptococcus pneumoniae.With this expansion, Genocea has got license to use Matrix M in vaccines for malaria and gonorrhoea.Genocea CEO Chip Clark said a safe and effective adjuvant that elicits strong B and T cell immune response is essential to their aim to prevent or treat infectious diseases. Isconova CEO Lena Soderstrom said they are pleased that a vaccine discovery and development company Genocea has selected Isconova’s Matrix M for use in two additional diseases, thus confirming the strengths of their products.
